Evidence map›Paper›PMID 25881829›Full record

ArticleBioorganic & medicinal chemistry letters2015

Synthetic derivatives of the SUMO consensus sequence provide a basis for improved substrate recognition.

Melissa J Leyva, Yeong Sang Kim, Megan L Peach, John S Schneekloth

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Current Status of SUMOylation Inhibitors.Current medicinal chemistry · 2021
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Melissa J LeyvaChemical Biology Laboratory, National Cancer Institute, 376 Boyles St., Frederick, MD 21702, USA.
Yeong Sang KimChemical Biology Laboratory, National Cancer Institute, 376 Boyles St., Frederick, MD 21702, USA.
Megan L PeachBasic Science Program, Chemical Biology Laboratory, Leidos Biomedical Research, Inc., National Cancer Institute, 376 Boyles St., Frederick, MD 21702, USA.
John S SchneeklothChemical Biology Laboratory, National Cancer Institute, 376 Boyles St., Frederick, MD 21702, USA. Electronic address: schneeklothjs@mail.nih.gov.
Frederick National Laboratory for Cancer Research · USLeidos (United States) · US

Funding

Identification of Inhibitors of Protein SumoylationZIABC011449 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHNEEKLOTH, JOHN · 2012 to 2019
$4.2M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC011449NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Protein sumoylation is a dynamic posttranslational modification that regulates a diverse subset of the proteome. The mechanism by which sumoylation enzymes recognize their cognate substrates is unclear, and the consequences of sumoylation remain difficult to predict. While small molecule probes of the sumoylation process could be valuable for understanding SUMO biology, few small molecules that modulate this process exist. Here, we report the synthesis and evaluation of over 600 oxime-containing peptide sumoylation substrates. Our work demonstrates that higher modification efficiency can be achieved with non-natural side chains that deviate substantially from the consensus site requirement of a hydrophobic substituent. Furthermore, docking studies suggest that these improved substrates mimic binding interactions that are used by other endogenous protein sequences through tertiary interactions. The development of these high efficiency substrates provides key mechanistic insights toward specific recognition of low molecular weight species in the sumoylation pathway.

Indexed as

Consensus SequenceSumoylationSmall Ubiquitin-Related Modifier ProteinsSubstrate SpecificitySmall Ubiquitin-Related Modifier ProteinsCombinatorial chemistryConjugationEnzymesPeptide mimicsSUMO

Identifiers

PMID25881829
PMCPMC6341477
OpenAlexW2010094620

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.